Enveric Biosciences (ENVB) Total Current Liabilities (2010 - 2026)
Enveric Biosciences (ENVB) posted Total Current Liabilities of $460676.0 for Q1 2026, down 49.84% sequentially from $918400.0 in Q4 2025, and down 61.1% YoY from $1.2 million in Q1 2025.
Enveric Biosciences (ENVB) Total Current Liabilities (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Total Current Liabilities for 17 years, with the latest figure at $460676.0 in Q1 2026.
- Quarterly Total Current Liabilities fell 61.1% year-over-year to $460676.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $460676.0 (down 61.1% YoY) and the FY2025 annual result came in at $918400.0, down 38.35% from the prior year.
- Total Current Liabilities declined to $460676.0 in Q1 2026 per ENVB's latest filing, from $918400.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $4.9 million in Q2 2023 and troughed at $460676.0 in Q1 2026.
- A 5-year average of $2.2 million and a median of $2.1 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities surged 233.92% in 2022, then tumbled 86.9% in 2024.
- Over 5 years, Total Current Liabilities stood at $4.0 million in 2022, then plunged by 41.35% to $2.3 million in 2023, then slumped by 36.43% to $1.5 million in 2024, then slumped by 38.35% to $918400.0 in 2025, then plunged by 49.84% to $460676.0 in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $460676.0, $918400.0, and $905885.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 630.93 Mn |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | 861,475.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 460,676.00 |
| Dec 31, 2025 | 918,400.00 |
| Sep 30, 2025 | 905,885.00 |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 839,166.00 |
| Jun 30, 2024 | 645,340.00 |
| Mar 31, 2024 | 2.37 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 4.18 Mn |
| Jun 30, 2023 | 4.93 Mn |
| Mar 31, 2023 | 4.44 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | 2.60 Mn |
| Jun 30, 2022 | 2.32 Mn |
| Mar 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 2.74 Mn |
| Sep 30, 2021 | 2.16 Mn |
| Jun 30, 2021 | 1.17 Mn |